Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc, a U.K.-incorporated global consumer-health company, filed this Form 6-K for April 2023. The filing reports the results of the company’s annual general meeting held on April 20, 2023; it is not a quarterly or annual financial-results filing.
Haleon’s principal categories are oral health, pain relief, respiratory health, digestive health, and vitamins, minerals and supplements. Key brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.
Financial metrics and liquidity
The filing does not provide current-period revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics. It records shareholder votes and corporate authorizations only.
Material changes versus the prior comparable period
No comparable-period financial information or material operating changes are provided. The principal reported development is the approval of the resolutions proposed at the 2023 AGM.
AGM results, outlook and risks
- All 29 resolutions passed. Resolutions 20, 21, 22, 26, 27 and 28 passed as special resolutions; the remaining resolutions passed as ordinary resolutions.
- Shareholders approved receipt of the annual report and accounts, the directors’ remuneration report and policy, and the final dividend.
- All listed director reappointments were approved, with votes in favor ranging from 98.27% to 99.96% of votes cast among all shareholders.
- KPMG LLP was appointed auditor, and the Audit & Risk Committee was authorized to determine the auditor’s remuneration.
- Shareholders approved authorities relating to share allotments, disapplication of pre-emption rights, political donations, share plans, and the company’s purchase of its own shares.
- Resolutions 27 and 28 authorized off-market purchases of shares from Pfizer and GSK shareholders, respectively. Those shareholder groups agreed not to vote the relevant shares on those resolutions.
- Resolution 29, approving a waiver of the Rule 9 takeover-offer obligation, passed with 97.47% of votes cast, excluding Pfizer and persons acting in concert with Pfizer from voting.
- Total issued share capital with voting rights at the relevant record time was 9,234,573,831 shares. Overall AGM participation generally represented approximately 85% of issued share capital, while certain resolutions involving excluded shareholders had lower participation.
- The filing contains no management earnings guidance, financial outlook, new operating-risk discussion, contingency disclosure, or unusual accounting item.
Most important facts to verify
- Review Haleon’s annual report and accounts for the underlying revenue, profitability, cash flow, debt, liquidity and dividend information, which are not reproduced in this Form 6-K.
- Confirm the terms and potential effect of the share-purchase authorities involving Pfizer and GSK shareholders.
- Verify the approved Rule 9 waiver and the related voting exclusions and ownership arrangements.
- Check the FCA National Storage Mechanism for copies of the resolutions filed under Listing Rule 9.6.2R.